ADVERTISEMENT

ADVERTISEMENT

» Home » Drug Database » Gastrointestinal Agent » sucralfate

sucralfate

Brand Name :

Carafate, Sucralfate, Cytogard, Suclrate Plus

Synonyms :

sucralfate

Class :

Drugs for peptic ulcer & Mucosal protectors

DRUG INTERACTION

sucralfate

&

sucralfate +

baloxavir marboxil

Sucralfate may reduce the serum concentration of balovir marboxile

bictegravir

Sucralfate may reduce the serum concentration of bictegravir

Sucralfate may reduce the serum concentration of cabotevir

deferiprone

Sucralfate may reduce the serum concentration of deferiprone

Sucralfate may diminish the serum concentration of digoxin

dolutegravir

Sucralfate may diminish the serum concentration of dolutegravir

elvitegravir

Sucralfate may diminish the serum concentration of elvitegravir

Sucralfate may diminish the serum concentration of furosemide

ketoconazole

Sucralfate may diminish the serum concentration of ketoconazole

levoketoconazole

Sucralfate may diminish the serum concentration of levoketoconazole

levothyroxine

Sucralfate may diminish the serum concentration of levothyroxin

paricalcitol

may enhance the serum concentration when combined with sucralfate

hydroxychloroquine

may diminish the serum concentration when combined with quinolones

sparfloxacin

may diminish the serum concentration when combined with quinolones

paricalcitol

may enhance the serum concentration of vitamin D analogs

moxifloxacin

may diminish the quinolones absorption

gemifloxacin

may diminish the serum concentration of quinolones

may increase the serum concentration of Vitamin D analogs

calcipotriene/betamethasone

may enhance the serum concentration of Vitamin D Analogs

anti-cholinergic agents may diminish the therapeutic effect of gastrointestinal agents

procyclidine

anti-cholinergic agents may diminish the therapeutic effect of gastrointestinal agents

anti-cholinergic agents may diminish the therapeutic effect of gastrointestinal agents

benztropine

anti-cholinergic agents may diminish the therapeutic effect of gastrointestinal agents

darifenacin hydrobromide

anti-cholinergic agents may diminish the therapeutic effect of gastrointestinal agents

It may enhance the effects when combined with vitamin D

may diminish the therapeutic effect

demeclocycline

demeclocycline may reduce the therapeutic effect of the other drug by affecting intestinal flora

doxycycline

doxycycline may reduce the therapeutic effect of the other drug by affecting intestinal flora

Dosage Forms & Strengths

Suspension, Oral:

1g/10ml

Tablet, Oral:

1g

Duodenal Ulcer

Initial:

1

g

tablet/suspension four times a day for 4 to 8 weeks.

Gastro Esophageal Reflux Disease (GERD)

1

g

suspension/tablet four times a day in combination with proton pump inhibitors

Oral Ulcers

1

g

suspension apply for 1 to 2 minutes directly to the oral ulcer 4 times a day

Due to radiation:

2g tablets/suspension dissolved in 20 ml water twice a day for 4 weeks or until resolution of symptoms

Upper GI Toxicity

1

g

Suspension

4 times a day

2

weeks

in combination with antisecretory agents

Dosage Forms & Strengths

Suspension, Oral:

1g/10ml

Tablet, Oral:

1g

Peptic Ulcer

40 - 80

mg/kg

Orally 

dose divided every 6 hours

per day

Esophagitis

Infants > 3 months and children <6 years:

500

mg

Orally 

4 times a day

Children > 6 years: 1000 mg/dose four times a day

Frequency defined:

1%-10%

Constipation

<1%:

Bronchospasm

Diarrhea

Dyspepsia

Facial edema

Hypersensitivity

Gastric distress

Headache

Mouth edema

Skin rash

Vertigo

Vomiting

Xerostomia

Insomnia

Pregnancy consideration: Sucralfate does not show any adverse fetal events when used during the first trimester.

Lactation: Excretion of sucralfate in breast milk is not known.

Pregnancy category:

Category A: Satisfactory and well-controlled studies show no risk to the fetus in the first or later trimester.
Category B: There is no evidence of risk to the fetus found in animal reproduction studies and there are not enough studies on pregnant women.
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for an effect in humans, care must be taken for potential risks in pregnant women
Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite potential risks may be used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh risks over benefits These category drugs should be prohibited for pregnant women.
Category N: There is no data available for the drug under this category.

Patient information leaflet

Generic Name: Sucralfate

Pronounced: Su-cra-l-fet

Why do we use sucralfate?

Sucralfate is a mucosal protector. It is used to treat GI & oral ulcers.

A middle-aged female with sudden onset of vision loss

Clinical Case

A middle-aged female with sudden onset of vision loss

September 27, 2023September 27, 2023

NASA Harnesses the Power of AI to Decode UFO Mysteries

News

NASA Harnesses the Power of AI to Decode UFO Mysteries

September 27, 2023September 27, 2023

T-Cell Therapy Might be Good Approach for Glioblastoma: Study

News

T-Cell Therapy Might be Good Approach for Glioblastoma: Study

September 27, 2023September 27, 2023

Metformin Targets Boost Cardiometabolic Health: Study

News

Metformin Targets Boost Cardiometabolic Health: Study

September 27, 2023September 27, 2023

ADVERTISEMENT

» Home » Drug Database » Gastrointestinal Agent » sucralfate

sucralfate

Brand Name :

Carafate, Sucralfate, Cytogard, Suclrate Plus

Synonyms :

sucralfate

Class :

Drugs for peptic ulcer & Mucosal protectors

Dosage Forms & Strengths

Suspension, Oral:

1g/10ml

Tablet, Oral:

1g

duodenal ulcer

Initial:

1

g

tablet/suspension four times a day for 4 to 8 weeks.

gastro esophageal reflux disease (GERD)

1

g

suspension/tablet four times a day in combination with proton pump inhibitors

oral ulcers

1

g

suspension apply for 1 to 2 minutes directly to the oral ulcer 4 times a day

Due to radiation:

2g tablets/suspension dissolved in 20 ml water twice a day for 4 weeks or until resolution of symptoms

upper GI toxicity

1

g

4 times a day

2

weeks

Suspension

in combination with antisecretory agents

Dosage Forms & Strengths

Suspension, Oral:

1g/10ml

Tablet, Oral:

1g

peptic ulcer

40 - 80

mg/kg

Orally 

dose divided every 6 hours

per day

esophagitis

Infants > 3 months and children <6 years:

500

mg

Orally 

4 times a day

Children > 6 years: 1000 mg/dose four times a day

DRUG INTERACTION

sucralfate

&

sucralfate +

baloxavir marboxil

Sucralfate may reduce the serum concentration of balovir marboxile

bictegravir

Sucralfate may reduce the serum concentration of bictegravir

Sucralfate may reduce the serum concentration of cabotevir

deferiprone

Sucralfate may reduce the serum concentration of deferiprone

Sucralfate may diminish the serum concentration of digoxin

dolutegravir

Sucralfate may diminish the serum concentration of dolutegravir

elvitegravir

Sucralfate may diminish the serum concentration of elvitegravir

Sucralfate may diminish the serum concentration of furosemide

ketoconazole

Sucralfate may diminish the serum concentration of ketoconazole

levoketoconazole

Sucralfate may diminish the serum concentration of levoketoconazole

levothyroxine

Sucralfate may diminish the serum concentration of levothyroxin

paricalcitol

may enhance the serum concentration when combined with sucralfate

hydroxychloroquine

may diminish the serum concentration when combined with quinolones

sparfloxacin

may diminish the serum concentration when combined with quinolones

paricalcitol

may enhance the serum concentration of vitamin D analogs

moxifloxacin

may diminish the quinolones absorption

gemifloxacin

may diminish the serum concentration of quinolones

may increase the serum concentration of Vitamin D analogs

calcipotriene/betamethasone

may enhance the serum concentration of Vitamin D Analogs

anti-cholinergic agents may diminish the therapeutic effect of gastrointestinal agents

procyclidine

anti-cholinergic agents may diminish the therapeutic effect of gastrointestinal agents

anti-cholinergic agents may diminish the therapeutic effect of gastrointestinal agents

benztropine

anti-cholinergic agents may diminish the therapeutic effect of gastrointestinal agents

darifenacin hydrobromide

anti-cholinergic agents may diminish the therapeutic effect of gastrointestinal agents

It may enhance the effects when combined with vitamin D

may diminish the therapeutic effect

demeclocycline

demeclocycline may reduce the therapeutic effect of the other drug by affecting intestinal flora

doxycycline

doxycycline may reduce the therapeutic effect of the other drug by affecting intestinal flora

Frequency defined:

1%-10%

Constipation

<1%:

Bronchospasm

Diarrhea

Dyspepsia

Facial edema

Hypersensitivity

Gastric distress

Headache

Mouth edema

Skin rash

Vertigo

Vomiting

Xerostomia

Insomnia

Pregnancy consideration: Sucralfate does not show any adverse fetal events when used during the first trimester.

Lactation: Excretion of sucralfate in breast milk is not known.

Pregnancy category:

Category A: Satisfactory and well-controlled studies show no risk to the fetus in the first or later trimester.
Category B: There is no evidence of risk to the fetus found in animal reproduction studies and there are not enough studies on pregnant women.
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for an effect in humans, care must be taken for potential risks in pregnant women
Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite potential risks may be used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh risks over benefits These category drugs should be prohibited for pregnant women.
Category N: There is no data available for the drug under this category.

Patient information leaflet

Generic Name: Sucralfate

Pronounced: Su-cra-l-fet

Why do we use sucralfate?

Sucralfate is a mucosal protector. It is used to treat GI & oral ulcers.

A middle-aged female with sudden onset of vision loss

Clinical Case

A middle-aged female with sudden onset of vision loss

September 27, 2023September 27, 2023

NASA Harnesses the Power of AI to Decode UFO Mysteries

News

NASA Harnesses the Power of AI to Decode UFO Mysteries

September 27, 2023September 27, 2023

T-Cell Therapy Might be Good Approach for Glioblastoma: Study

News

T-Cell Therapy Might be Good Approach for Glioblastoma: Study

September 27, 2023September 27, 2023

Metformin Targets Boost Cardiometabolic Health: Study

News

Metformin Targets Boost Cardiometabolic Health: Study

September 27, 2023September 27, 2023

ADVERTISEMENT

medtigo

sucralfate

Brand Name :

Carafate, Sucralfate, Cytogard, Suclrate Plus

Synonyms :

sucralfate

Class :

Drugs for peptic ulcer & Mucosal protectors

Action and Spectrum

Dosing & Uses

Drug Interaction

Adverse Reaction

Frequency defined:

1%-10%

Constipation

<1%:

Bronchospasm

Diarrhea

Dyspepsia

Facial edema

Hypersensitivity

Gastric distress

Headache

Mouth edema

Skin rash

Vertigo

Vomiting

Xerostomia

Insomnia

Black Box Warning

Contraindication / Caution

Pregnancy / Lactation

Pregnancy consideration: Sucralfate does not show any adverse fetal events when used during the first trimester.

Lactation: Excretion of sucralfate in breast milk is not known.

Pregnancy category:

Category A: Satisfactory and well-controlled studies show no risk to the fetus in the first or later trimester.
Category B: There is no evidence of risk to the fetus found in animal reproduction studies and there are not enough studies on pregnant women.
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for an effect in humans, care must be taken for potential risks in pregnant women
Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite potential risks may be used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh risks over benefits These category drugs should be prohibited for pregnant women.
Category N: There is no data available for the drug under this category.

Pharmacology

Adminstartion

Patient Information Leaflet

Patient information leaflet

Generic Name: Sucralfate

Pronounced: Su-cra-l-fet

Why do we use sucralfate?

Sucralfate is a mucosal protector. It is used to treat GI & oral ulcers.

Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.

CONTACT INFORMATION

ADDRESS

USA – BOSTON

60 Roberts Drive, Suite 313
North Adams, MA 01247

INDIA – PUNE

7, Shree Krishna, 2nd Floor, Opp Kiosk Koffee, Shirole Lane, Off FC Road, Pune 411004, Maharashtra

JOIN THE FASTEST GROWING HEALTHCARE COMMUNITY!

Download our APP

Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.

CONTACT INFORMATION

ADDRESS

MASSACHUSETTS – USA

60 Roberts Drive, Suite 313,
North Adams, MA 01247

MAHARASHTRA – INDIA

7, Shree Krishna, 2nd Floor,
Opp Kiosk Koffee,
Shirole Lane, Off FC Road,
Pune 411004, Maharashtra

Taking the Pain out of Your Career

DOWNLOAD APP